Patent US5177062A successfully refreshed from Google Patents.
US5177062A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for treating immune complex diseases with n-acetylneuraminic acid
Assignee: Mect Corp
•
Filing: 1989-03-20
•
Granted: 1993-01-05
•
Expires: 2009-03-20
Abstract
Abstract A preparation for treating immune complex diseases which comprises injection containing the following compound: ##STR1## wherein when n is 1, Z represents a hydrogen, lithium, potassium, sodium, ammonium or organic ammonium, and when n is 2, Z represents calcium, barium or magnesium, as an active ingredient and pharmacologically acceptable carrier. The preparation of the present invention may be used in any administration method such as hypodermic, intramuscular and intravenous.
Inventors
- 👤 Takeshi Miyata
- 👤 Kazuo Takahama
- 👤 Hirofumi Kai
- 👤 Takayuki Ishii
- 👤 Keiji Komatsu
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 15:36
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/7004
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
74 words
A method for treating immune complex diseases characterized by an Arthus type inflammatory response in an animal, which comprises administering to said animal a preparation containing an effective amount of a compound represented by the formula: ##STR3## as the active ingredient, wherein when n is 1, Z represents a hydrogen, lithium, potassium, sodium, ammonium or an organic ammonium; and when n is 2, Z represents calcium, barium or magnesium; and a pharmaceutically acceptable carrier.
Claim 2
Independent Claim
74 words
A method for treating immune complex diseases characterized by an Arthus type inflammatory response in an animal, which comprises administering to said animal a preparation containing an effective amount of a compound represented by the formula: ##STR3## as the active ingredient, wherein when n is 1, Z represents a hydrogen, lithium, potassium, sodium, ammonium or an organic ammonium; and when n is 2, Z represents calcium, barium or magnesium; and a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim
19 words
The method of claim 1, wherein the preparation comprises about 0.1 to 10% by weight of the active ingredient.
Claim 4
Dependent Claim
21 words
The method of claim 1, wherein the active ingredient is selected from the group consisting of sodium N-acetylneuraminate and potassium N-acetylneuraminate.
Claim 5
Dependent Claim
14 words
The method according to claim 1, wherein said preparation is administered by injection means.
Claim 6
Dependent Claim
22 words
The method according to claim 4, wherein said injection means is selected from the group consisting of hypodermic, intramuscular and intravenous injections.
Claim 7
Dependent Claim
21 words
The method of claim 1, wherein the preparation is made from a powder that is dissolved in solution prior to use.
Claim 8
Dependent Claim
32 words
The method of claim 1, wherein the preparation also contains at least one agent as a carrier selected from the group consisting of stabilizers, buffers, isotonic agents, excipients, pH adjusters and preservatives.
References Cited (Backward Citations)
US4663443A
Cited
JPS61283990A
Cited
DE3624816A1
Cited
US4762822A
Cited
US4774326A
Cited
JPS62221694A
Cited
JPS6344589A
Cited
US4797477A
Cited
EP0273388A2
Cited
JPS63222192A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-01-05 | 1996-07-06 | 1997-01-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-01-05 | 2000-07-06 | 2001-01-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-01-05 | 2004-07-06 | 2005-01-05 | $7700.00 | Window Closed / Lapsed |